Evidence map›Paper›PMID 22315164›Full record

ReviewChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2012

Matching mice to malignancy: molecular subgroups and models of medulloblastoma.

Jasmine Lau, Christin Schmidt, Shirley L Markant, Michael D Taylor, Robert J Wechsler-Reya, William A Weiss

Abstract readReview
In one paragraph

Review in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Modeling pediatric medulloblastoma.Brain pathology (Zurich, Switzerland) · 2020
    Review
  2. Article
  3. Article
  4. Medulloblastoma in the Molecular Era.Journal of Korean Neurosurgical Society · 2018
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Molecular subgroups of medulloblastoma.Expert review of neurotherapeutics · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jasmine LauDepartment of Neurology, University of California, San Francisco, CA, USA.
Christin Schmidt
Shirley L Markant
Michael D Taylor
Robert J Wechsler-Reya
William A Weiss

Funding

Mouse models to discover new drivers of medulloblastomaR01CA159859 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Michael D. Taylor, WILLIAM A WEISS · 2011 to 2026
$10.4M
Murine Neuroblastoma Models for Preclinical TherapeuticsR01CA102321 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WEISS, WILLIAM A · 2003 to 2016
$3.4M
Medulloblastoma and MetastasesR01CA148699 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI TAYLOR, MICHAEL D., WEISS, WILLIAM A · 2010 to 2014
$2.4M
Stem Cells, Progenitors, and the Origin of MedulloblastomaR01CA122759 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI WECHSLER-REYA, ROBERT J. · 2009 to 2013
$1.8M
Mycn and MedulloblastomaR01CA133091 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WEISS, WILLIAM A · 2009 to 2013
$1.6M
NCI NIH HHS R01 CA102321NCI NIH HHS R01 CA122759NCI NIH HHS R01CA122759NCI NIH HHS R01 CA133091NCI NIH HHS R01CA133091NCI NIH HHS R01 CA148699NCI NIH HHS R01CA148699NCI NIH HHS R01 CA159859NCI NIH HHS R01CA159859
6 · The paper itself

Abstract

introductionMedulloblastoma, the largest group of embryonal brain tumors, has historically been classified into five variants based on histopathology. More recently, epigenetic and transcriptional analyses of primary tumors have subclassified medulloblastoma into four to six subgroups, most of which are incongruous with histopathological classification. DISCUSSION: Improved stratification is required for prognosis and development of targeted treatment strategies, to maximize cure and minimize adverse effects. Several mouse models of medulloblastoma have contributed both to an improved understanding of progression and to developmental therapeutics. In this review, we summarize the classification of human medulloblastoma subtypes based on histopathology and molecular features. We describe existing genetically engineered mouse models, compare these to human disease, and discuss the utility of mouse models for developmental therapeutics. Just as accurate knowledge of the correct molecular subtype of medulloblastoma is critical to the development of targeted therapy in patients, we propose that accurate modeling of each subtype of medulloblastoma in mice will be necessary for preclinical evaluation and optimization of those targeted therapies.

Indexed as

Disease Models, AnimalAnimalsAntineoplastic AgentsCerebellar NeoplasmsDrug Delivery SystemsHumansMedulloblastomaMiceNeoplasms, Germ Cell and EmbryonalSpecies SpecificityAntineoplastic Agents

Identifiers

PMID22315164
PMCPMC3515664

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.